Investment analysts at Maxim Group assumed coverage on shares of Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) in a note issued to investors on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $2.00 price target on the stock. Maxim Group’s price target indicates a potential upside of 167.85% from the company’s previous […]
Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership. Analyst Recommendations This is a breakdown of […]
Lipella Pharmaceuticals’ (NASDAQ:LIPO – Get Rating) lock-up period will expire on Monday, June 19th. Lipella Pharmaceuticals had issued 1,217,391 shares in its IPO on December 20th. The total size of the offering was $6,999,998 based on an initial share price of $5.75. Shares of the company owned by company insiders and major shareholders will be […]
Lipella Pharmaceuticals (NASDAQ:LIPO – Get Rating) and Veru (NASDAQ:VERU – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares Lipella Pharmaceuticals and Veru’s net margins, […]